Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

New Insight Into Hyperemesis Gravidarum and a Potential Role for GDF15.

Walker RG, Thompson TB.

Endocrinology. 2018 Jul 1;159(7):2698-2700. doi: 10.1210/en.2018-00439. No abstract available.

PMID:
29846562
2.

A thumbwheel mechanism for APOA1 activation of LCAT activity in HDL.

Cooke AL, Morris J, Melchior JT, Street SE, Jerome WG, Huang R, Herr AB, Smith LE, Segrest JP, Remaley AT, Shah AS, Thompson TB, Davidson WS.

J Lipid Res. 2018 Jul;59(7):1244-1255. doi: 10.1194/jlr.M085332. Epub 2018 May 17.

PMID:
29773713
3.

Molecular characterization of latent GDF8 reveals mechanisms of activation.

Walker RG, McCoy JC, Czepnik M, Mills MJ, Hagg A, Walton KL, Cotton TR, Hyvönen M, Lee RT, Gregorevic P, Harrison CA, Thompson TB.

Proc Natl Acad Sci U S A. 2018 Jan 30;115(5):E866-E875. doi: 10.1073/pnas.1714622115. Epub 2018 Jan 18.

PMID:
29348202
4.

Structure of the human myostatin precursor and determinants of growth factor latency.

Cotton TR, Fischer G, Wang X, McCoy JC, Czepnik M, Thompson TB, Hyvönen M.

EMBO J. 2018 Feb 1;37(3):367-383. doi: 10.15252/embj.201797883. Epub 2018 Jan 12.

PMID:
29330193
5.

A consensus model of human apolipoprotein A-I in its monomeric and lipid-free state.

Melchior JT, Walker RG, Cooke AL, Morris J, Castleberry M, Thompson TB, Jones MK, Song HD, Rye KA, Oda MN, Sorci-Thomas MG, Thomas MJ, Heinecke JW, Mei X, Atkinson D, Segrest JP, Lund-Katz S, Phillips MC, Davidson WS.

Nat Struct Mol Biol. 2017 Dec;24(12):1093-1099. doi: 10.1038/nsmb.3501. Epub 2017 Nov 13.

6.

Correction: Analysis and identification of the Grem2 heparin/heparan sulfate-binding motif.

Kattamuri C, Nolan K, Thompson TB.

Biochem J. 2017 Apr 24;474(9):1529. doi: 10.1042/BCJ-2016-1050_COR. No abstract available.

PMID:
28439042
7.

Structural basis for potency differences between GDF8 and GDF11.

Walker RG, Czepnik M, Goebel EJ, McCoy JC, Vujic A, Cho M, Oh J, Aykul S, Walton KL, Schang G, Bernard DJ, Hinck AP, Harrison CA, Martinez-Hackert E, Wagers AJ, Lee RT, Thompson TB.

BMC Biol. 2017 Mar 3;15(1):19. doi: 10.1186/s12915-017-0350-1.

8.

Coordinated Proliferation and Differentiation of Human-Induced Pluripotent Stem Cell-Derived Cardiac Progenitor Cells Depend on Bone Morphogenetic Protein Signaling Regulation by GREMLIN 2.

Bylund JB, Trinh LT, Awgulewitsch CP, Paik DT, Jetter C, Jha R, Zhang J, Nolan K, Xu C, Thompson TB, Kamp TJ, Hatzopoulos AK.

Stem Cells Dev. 2017 May 1;26(9):678-693. doi: 10.1089/scd.2016.0226. Epub 2017 Mar 20.

9.

Analysis and identification of the Grem2 heparin/heparan sulfate-binding motif.

Kattamuri C, Nolan K, Thompson TB.

Biochem J. 2017 Mar 8;474(7):1093-1107. doi: 10.1042/BCJ20161050. Erratum in: Biochem J. 2017 Apr 24;474(9):1529.

10.

MuSK is a BMP co-receptor that shapes BMP responses and calcium signaling in muscle cells.

Yilmaz A, Kattamuri C, Ozdeslik RN, Schmiedel C, Mentzer S, Schorl C, Oancea E, Thompson TB, Fallon JR.

Sci Signal. 2016 Sep 6;9(444):ra87. doi: 10.1126/scisignal.aaf0890.

11.

Structure of Gremlin-2 in Complex with GDF5 Gives Insight into DAN-Family-Mediated BMP Antagonism.

Nolan K, Kattamuri C, Rankin SA, Read RJ, Zorn AM, Thompson TB.

Cell Rep. 2016 Aug 23;16(8):2077-2086. doi: 10.1016/j.celrep.2016.07.046. Epub 2016 Aug 11.

12.

BMP Antagonist Gremlin 2 Limits Inflammation After Myocardial Infarction.

Sanders LN, Schoenhard JA, Saleh MA, Mukherjee A, Ryzhov S, McMaster WG Jr, Nolan K, Gumina RJ, Thompson TB, Magnuson MA, Harrison DG, Hatzopoulos AK.

Circ Res. 2016 Jul 22;119(3):434-49. doi: 10.1161/CIRCRESAHA.116.308700. Epub 2016 Jun 9.

13.

Biochemistry and Biology of GDF11 and Myostatin: Similarities, Differences, and Questions for Future Investigation.

Walker RG, Poggioli T, Katsimpardi L, Buchanan SM, Oh J, Wattrus S, Heidecker B, Fong YW, Rubin LL, Ganz P, Thompson TB, Wagers AJ, Lee RT.

Circ Res. 2016 Apr 1;118(7):1125-41; discussion 1142. doi: 10.1161/CIRCRESAHA.116.308391. Review.

14.

An Evaluation of the Crystal Structure of C-terminal Truncated Apolipoprotein A-I in Solution Reveals Structural Dynamics Related to Lipid Binding.

Melchior JT, Walker RG, Morris J, Jones MK, Segrest JP, Lima DB, Carvalho PC, Gozzo FC, Castleberry M, Thompson TB, Davidson WS.

J Biol Chem. 2016 Mar 4;291(10):5439-51. doi: 10.1074/jbc.M115.706093. Epub 2016 Jan 11.

15.

Myostatin Attenuation In Vivo Reduces Adiposity, but Activates Adipogenesis.

Li N, Yang Q, Walker RG, Thompson TB, Du M, Rodgers BD.

Endocrinology. 2016 Jan;157(1):282-91. doi: 10.1210/en.2015-1546. Epub 2015 Nov 18.

16.

Circulating Growth Differentiation Factor 11/8 Levels Decline With Age.

Poggioli T, Vujic A, Yang P, Macias-Trevino C, Uygur A, Loffredo FS, Pancoast JR, Cho M, Goldstein J, Tandias RM, Gonzalez E, Walker RG, Thompson TB, Wagers AJ, Fong YW, Lee RT.

Circ Res. 2016 Jan 8;118(1):29-37. doi: 10.1161/CIRCRESAHA.115.307521. Epub 2015 Oct 21. Erratum in: Circ Res. 2018 Jan 5;122(1):e3-e4.

17.

Acute respiratory distress syndrome in patients with and without diffuse alveolar damage: an autopsy study.

Lorente JA, Cardinal-Fernández P, Muñoz D, Frutos-Vivar F, Thille AW, Jaramillo C, Ballén-Barragán A, Rodríguez JM, Peñuelas O, Ortiz G, Blanco J, Pinheiro BV, Nin N, del Carmen Marin M, Esteban A, Thompson TB.

Intensive Care Med. 2015 Nov;41(11):1921-30. doi: 10.1007/s00134-015-4046-0. Epub 2015 Sep 18.

PMID:
26385863
18.

Role of Conserved Proline Residues in Human Apolipoprotein A-IV Structure and Function.

Deng X, Walker RG, Morris J, Davidson WS, Thompson TB.

J Biol Chem. 2015 Apr 24;290(17):10689-702. doi: 10.1074/jbc.M115.637058. Epub 2015 Mar 2.

19.

Alternative binding modes identified for growth and differentiation factor-associated serum protein (GASP) family antagonism of myostatin.

Walker RG, Angerman EB, Kattamuri C, Lee YS, Lee SJ, Thompson TB.

J Biol Chem. 2015 Mar 20;290(12):7506-16. doi: 10.1074/jbc.M114.624130. Epub 2015 Feb 5.

20.

Fibronectin-based scaffold domain proteins that bind myostatin: a patent evaluation of WO2014043344.

Walker RG, Thompson TB.

Expert Opin Ther Pat. 2015 May;25(5):619-24. doi: 10.1517/13543776.2015.1007954. Epub 2015 Jan 29.

PMID:
25632990
21.

Structure of neuroblastoma suppressor of tumorigenicity 1 (NBL1): insights for the functional variability across bone morphogenetic protein (BMP) antagonists.

Nolan K, Kattamuri C, Luedeke DM, Angerman EB, Rankin SA, Stevens ML, Zorn AM, Thompson TB.

J Biol Chem. 2015 Feb 20;290(8):4759-71. doi: 10.1074/jbc.M114.628412. Epub 2015 Jan 5.

22.

Amino acid 72 of mouse and human GDF9 mature domain is responsible for altered homodimer bioactivities but has subtle effects on GDF9:BMP15 heterodimer activities.

Peng J, Wigglesworth K, Rangarajan A, Eppig JJ, Thompson TB, Matzuk MM.

Biol Reprod. 2014 Dec;91(6):142. doi: 10.1095/biolreprod.114.123158. Epub 2014 Sep 24.

23.

The DAN family: modulators of TGF-β signaling and beyond.

Nolan K, Thompson TB.

Protein Sci. 2014 Aug;23(8):999-1012. doi: 10.1002/pro.2485. Epub 2014 Jun 2. Review.

24.

The structure of human apolipoprotein A-IV as revealed by stable isotope-assisted cross-linking, molecular dynamics, and small angle x-ray scattering.

Walker RG, Deng X, Melchior JT, Morris J, Tso P, Jones MK, Segrest JP, Thompson TB, Davidson WS.

J Biol Chem. 2014 Feb 28;289(9):5596-608. doi: 10.1074/jbc.M113.541037. Epub 2014 Jan 14.

25.

Myostatin stimulates, not inihibits, C2C12 myoblast proliferation.

Rodgers BD, Wiedeback BD, Hoversten KE, Jackson MF, Walker RG, Thompson TB.

Endocrinology. 2014 Mar;155(3):670-5. doi: 10.1210/en.2013-2107. Epub 2014 Jan 1.

26.

Activins bind and signal via bone morphogenetic protein receptor type II (BMPR2) in immortalized gonadotrope-like cells.

Rejon CA, Hancock MA, Li YN, Thompson TB, Hébert TE, Bernard DJ.

Cell Signal. 2013 Dec;25(12):2717-26. doi: 10.1016/j.cellsig.2013.09.002. Epub 2013 Sep 7.

PMID:
24018044
27.

Reply to Mottershead et al.: GDF9:BMP15 heterodimers are potent regulators of ovarian functions.

Peng J, Li Q, Wigglesworth K, Rangarajan A, Kattamuri C, Peterson RT, Eppig JJ, Thompson TB, Matzuk MM.

Proc Natl Acad Sci U S A. 2013 Jun 18;110(25):E2258. No abstract available.

28.

Structure of protein related to Dan and Cerberus: insights into the mechanism of bone morphogenetic protein antagonism.

Nolan K, Kattamuri C, Luedeke DM, Deng X, Jagpal A, Zhang F, Linhardt RJ, Kenny AP, Zorn AM, Thompson TB.

Structure. 2013 Aug 6;21(8):1417-29. doi: 10.1016/j.str.2013.06.005. Epub 2013 Jul 11.

29.

Development of a small-molecule screening method for inhibitors of cellular response to myostatin and activin A.

Cash JN, Angerman EB, Kirby RJ, Merck L, Seibel WL, Wortman MD, Papoian R, Nelson S, Thompson TB.

J Biomol Screen. 2013 Aug;18(7):837-44. doi: 10.1177/1087057113482585. Epub 2013 Mar 29.

PMID:
23543431
30.

Growth differentiation factor 9:bone morphogenetic protein 15 heterodimers are potent regulators of ovarian functions.

Peng J, Li Q, Wigglesworth K, Rangarajan A, Kattamuri C, Peterson RT, Eppig JJ, Thompson TB, Matzuk MM.

Proc Natl Acad Sci U S A. 2013 Feb 19;110(8):E776-85. doi: 10.1073/pnas.1218020110. Epub 2013 Feb 4.

31.

Small-angle X-ray scattering of apolipoprotein A-IV reveals the importance of its termini for structural stability.

Deng X, Morris J, Chaton C, Schröder GF, Davidson WS, Thompson TB.

J Biol Chem. 2013 Feb 15;288(7):4854-66. doi: 10.1074/jbc.M112.436709. Epub 2013 Jan 3.

32.

Members of the DAN family are BMP antagonists that form highly stable noncovalent dimers.

Kattamuri C, Luedeke DM, Nolan K, Rankin SA, Greis KD, Zorn AM, Thompson TB.

J Mol Biol. 2012 Dec 14;424(5):313-27. doi: 10.1016/j.jmb.2012.10.003. Epub 2012 Oct 9.

33.

Analysis of the interaction between heparin and follistatin and heparin and follistatin-ligand complexes using surface plasmon resonance.

Zhang F, Beaudet JM, Luedeke DM, Walker RG, Thompson TB, Linhardt RJ.

Biochemistry. 2012 Aug 28;51(34):6797-803. Epub 2012 Aug 13.

34.

Characterization of follistatin-type domains and their contribution to myostatin and activin A antagonism.

Cash JN, Angerman EB, Keutmann HT, Thompson TB.

Mol Endocrinol. 2012 Jul;26(7):1167-78. doi: 10.1210/me.2012-1061. Epub 2012 May 16.

35.

The structure of dimeric apolipoprotein A-IV and its mechanism of self-association.

Deng X, Morris J, Dressmen J, Tubb MR, Tso P, Jerome WG, Davidson WS, Thompson TB.

Structure. 2012 May 9;20(5):767-79. doi: 10.1016/j.str.2012.02.020.

36.

Expression and purification of recombinant protein related to DAN and cerberus (PRDC).

Kattamuri C, Luedeke DM, Thompson TB.

Protein Expr Purif. 2012 Apr;82(2):389-95. doi: 10.1016/j.pep.2012.02.010. Epub 2012 Feb 20.

37.

Improving the diffraction of apoA-IV crystals through extreme dehydration.

Deng X, Davidson WS, Thompson TB.

Acta Crystallogr Sect F Struct Biol Cryst Commun. 2012 Jan 1;68(Pt 1):105-10. doi: 10.1107/S1744309111048706. Epub 2011 Dec 24.

38.

Structure of myostatin·follistatin-like 3: N-terminal domains of follistatin-type molecules exhibit alternate modes of binding.

Cash JN, Angerman EB, Kattamuri C, Nolan K, Zhao H, Sidis Y, Keutmann HT, Thompson TB.

J Biol Chem. 2012 Jan 6;287(2):1043-53. doi: 10.1074/jbc.M111.270801. Epub 2011 Nov 3.

39.

Cytochrome b₅ reductase-cytochrome b₅ as an active P450 redox enzyme system in Phanerochaete chrysosporium: atypical properties and in vivo evidence of electron transfer capability to CYP63A2.

Syed K, Kattamuri C, Thompson TB, Yadav JS.

Arch Biochem Biophys. 2011 May 1;509(1):26-32. doi: 10.1016/j.abb.2011.02.023. Epub 2011 Mar 2.

40.

Bedside quantification of dead-space fraction using routine clinical data in patients with acute lung injury: secondary analysis of two prospective trials.

Siddiki H, Kojicic M, Li G, Yilmaz M, Thompson TB, Hubmayr RD, Gajic O.

Crit Care. 2010;14(4):R141. doi: 10.1186/cc9206. Epub 2010 Jul 29. Erratum in: Crit Care. 2011;15(2):410.

41.

The structure of myostatin:follistatin 288: insights into receptor utilization and heparin binding.

Cash JN, Rejon CA, McPherron AC, Bernard DJ, Thompson TB.

EMBO J. 2009 Sep 2;28(17):2662-76. doi: 10.1038/emboj.2009.205. Epub 2009 Jul 30.

42.

The structure of FSTL3.activin A complex. Differential binding of N-terminal domains influences follistatin-type antagonist specificity.

Stamler R, Keutmann HT, Sidis Y, Kattamuri C, Schneyer A, Thompson TB.

J Biol Chem. 2008 Nov 21;283(47):32831-8. doi: 10.1074/jbc.M801266200. Epub 2008 Sep 2.

43.

The structure of apolipoprotein A-I in high density lipoproteins.

Davidson WS, Thompson TB.

J Biol Chem. 2007 Aug 3;282(31):22249-53. Epub 2007 May 25. Review. No abstract available.

44.

Genotypes and haplotypes of the VEGF gene are associated with higher mortality and lower VEGF plasma levels in patients with ARDS.

Zhai R, Gong MN, Zhou W, Thompson TB, Kraft P, Su L, Christiani DC.

Thorax. 2007 Aug;62(8):718-22. Epub 2007 Feb 8.

45.

The structure of the follistatin:activin complex reveals antagonism of both type I and type II receptor binding.

Thompson TB, Lerch TF, Cook RW, Woodruff TK, Jardetzky TS.

Dev Cell. 2005 Oct;9(4):535-43.

46.

Structural basis for a functional antagonist in the transforming growth factor beta superfamily.

Cook RW, Thompson TB, Kurup SP, Jardetzky TS, Woodruff TK.

J Biol Chem. 2005 Dec 2;280(48):40177-86. Epub 2005 Sep 26.

47.

Structural studies of the parainfluenza virus 5 hemagglutinin-neuraminidase tetramer in complex with its receptor, sialyllactose.

Yuan P, Thompson TB, Wurzburg BA, Paterson RG, Lamb RA, Jardetzky TS.

Structure. 2005 May;13(5):803-15.

48.

Beta A versus beta B: is it merely a matter of expression?

Thompson TB, Cook RW, Chapman SC, Jardetzky TS, Woodruff TK.

Mol Cell Endocrinol. 2004 Oct 15;225(1-2):9-17. Review.

PMID:
15451562
49.

Molecular biology of inhibin action.

Cook RW, Thompson TB, Jardetzky TS, Woodruff TK.

Semin Reprod Med. 2004 Aug;22(3):269-76. Review.

PMID:
15319829
50.

Structural and functional analysis of tetracenomycin F2 cyclase from Streptomyces glaucescens. A type II polyketide cyclase.

Thompson TB, Katayama K, Watanabe K, Hutchinson CR, Rayment I.

J Biol Chem. 2004 Sep 3;279(36):37956-63. Epub 2004 Jun 30.

Supplemental Content

Loading ...
Support Center